ABSTRACT
Dengue is considered a critical worldwide health concern with an estimated 3.6 billion people at risk of infection and approximately 390 million infected annually of which 96 million are present with clinically overt disease. Most subjects recover from Dengue incurring asymptomatic or subclinical disease; however, progression can take the form of more dangerous dengue fever (DF), most severe dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue virus (DENV) belongs to the Flaviviridae family of single positive-stranded ribonucleic acid viruses of the genus Flavivirus. Although a DENV vaccine with variable serotype efficacy is available, there is still an urgent need to develop small molecule inhibitors to support the treatment of DHF and DSS. The chapter presents a summary of drugs repurposed as DENV inhibitors and even though most did not demonstrate substantial efficacy they represent a suitable and advanced starting point to develop new treatments.
